The resulting nanoparticles had a size of ~160 nm and a positive charge; their capacity to specifically target HER2-expressing breast cancer cells was confirmed both in vitro and in vivo, where treatment with the targeted nano-formulation led to both the reduction of primary tumor growth and inhibition of lung metastasis in an orthotopic mouse model of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.